- Category: HIV Treatment
- Published on Monday, 08 July 2013 00:00
- Written by Gregory Fowler
A second-line regimen of a protease inhibitor plus either 2 NRTIs or raltegravir (Isentress) led to good outcomes for people with HIV in Africa after initial regimen failure, according to a study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.
In contrast, Nicholas Paton reported, the EARNEST (Europe-Africa Research Network for Evaluation of Second-line Therapy)study found that protease inhibitor monotherapy following raltegravir induction did not work as well.
Patongave a summary of the EARNEST results at a press conference prior to his late-breaker presentation.
[Nicholas Paton speaks at IAS 2013 press conference, Kuala Lumpur, July 1, 2013]
N Paton, C Kityo, A Hoppe, et al. A pragmatic randomised controlled strategy trial of three second-line treatment options for use in public health rollout programme settings: the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013). Kuala Lumpur, June 30-July 3, 2013. Abstract WELBB02.